The head of Forest Laboratories, Howard Solomon, is reportedly slated to make $100 million or more from his company’s $25 billion merger with pharmaceutical giant Actavis, according to reports.
Reports say documents recently filed with the US Securities and Exchange Commission suggest Actavis is preparing to acquire Forest, a notice that hints at corporate restructuring at the firm.
According to reports, Solomon stands to reap major profits from the deal before he is set to leave his position as chairman after the company’s annual meeting later this year.
Full content: Fierce Pharma
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.